Home Tags Revance

Tag: Revance

Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines – Revance Therapeutics (NASD – Benzinga
Injectables

Revance Shares Shoot Higher As FDA Cleared DAXXIFY Injection For Frown Lines – Revance Therapeutics (NASD – Benzinga

Esthetic Advisor -
0
Revance to Present New DAXXIFY ® Data at the American Academy of Neurology 2024 Annual Meeting – Investing.com South Africa
Injectables

Revance to Present New DAXXIFY ® Data at the American Academy of Neurology 2024 Annual Meeting – Investing.com South Africa

Esthetic Advisor -
0
Revance sets $100 million stock offering at $6.25 per share By Investing.com – Investing.com Canada
Injectables

Revance sets $100 million stock offering at $6.25 per share By Investing.com – Investing.com Canada

Esthetic Advisor -
0
Revance sets $100 million stock offering at $6.25 per share By Investing.com – Investing.com Australia
Injectables

Revance sets $100 million stock offering at $6.25 per share By Investing.com – Investing.com Australia

Esthetic Advisor -
0
What is the Market's View on Revance Therapeutics Inc (RVNC) Stock's Price and Volume Trends Friday? – InvestorsObserver
Injectables

What is the Market's View on Revance Therapeutics Inc (RVNC) Stock's Price and Volume Trends Friday? – InvestorsObserver

Esthetic Advisor -
0
Is Revance Therapeutics Inc (RVNC) Stock About to Get Hot Friday? – InvestorsObserver
Injectables

Is Revance Therapeutics Inc (RVNC) Stock About to Get Hot Friday? – InvestorsObserver

Esthetic Advisor -
0
Revance Announces Phase 2 DAXI Results – Dermatology Times
Injectables

Revance Announces Phase 2 DAXI Results – Dermatology Times

Esthetic Advisor -
0
Where Will Revance Therapeutics Inc (RVNC) Stock Go Next After It Is Up 4.72% in a Week? – InvestorsObserver
Injectables

Where Will Revance Therapeutics Inc (RVNC) Stock Go Next After It Is Up 4.72% in a Week? – InvestorsObserver

Esthetic Advisor -
0
Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management – AiThority
Injectables

Revance Closes on $300 Million Note Purchase Agreement with Athyrium Capital Management – AiThority

Esthetic Advisor -
0
Revance sets $100 million stock offering at $6.25 per share By Investing.com – Investing.com UK
Injectables

Revance sets $100 million stock offering at $6.25 per share By Investing.com – Investing.com UK

Esthetic Advisor -
0
123...66Page 1 of 66
© Newspaper WordPress Theme by TagDiv